Claims for Patent: 10,238,656

Summary for Patent: 10,238,656

Title:	Combination therapy for cancer
Abstract:	The present invention provides preparation of medicaments for use in treating and methods of treating non-small cell lung cancer in a patient comprising: [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-i- sopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, in combination, as further described herein, with an anti-VEGFR2 antibody, preferably, ramucirumab.
Inventor(s):	Chan; Edward Michael (Greenwood, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	15/115,995
Patent Claims:	1. A method of treating non-small cell lung cancer in a human patient, comprising administering to a non-small cell lung cancer human patient in need of such treatment 300 or 400 mg daily of a compound of the formula: ##STR00005## or a pharmaceutically acceptable salt thereof, in combination with 10 mg/kg once every three weeks of ramucirumab. 2. The method of claim 1, wherein the compound is ##STR00006## 3. The method of claim 1 wherein the compound or salt thereof is administered orally and ramucirumab is administered intravenously. 4. A method of treating non-small cell lung cancer in a human patient, comprising administering to a non-small cell lung cancer human patient in need of such treatment 300 or 400 mg daily of a compound of the formula: ##STR00007## or a pharmaceutically acceptable salt thereof, in combination with 10 mg/kg of ramucirumab on the first day of a 21-day cycle. 5. The method of claim 4, wherein the compound is ##STR00008## 6. The method of claim 4 wherein the compound or salt thereof is administered orally and ramucirumab is administered intravenously.

Details for Patent 10,238,656

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	CYRAMZA	ramucirumab	Injection	125477	04/21/2014		2039-04-26